GlassScriptPhysician profile
Veena V Sengupta
NPI 1548329352
$10,197.46
in general payments reported to CMS, 2019-2025
41 companies · $2,678 in 2025
The $2,678 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $563 · 2021: $961 · 2022: $1,045 · 2023: $1,625 · 2024: $2,486 · 2025: $2,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,579 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,579.27 |
| Education | $210.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,896.22 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbvie INC. | $1,436.82 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $833.19 | 2023-2025 | |
| Emd Serono, INC. | $599.31 | 2019-2025 | Mavenclad, Mavenclad |
| Biohaven Pharmaceuticals, INC. | $588.57 | 2020-2021 | |
| Neurelis, INC. | $507.81 | 2021-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $447.14 | 2020-2025 | |
| Eisai INC. | $322.78 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $316.86 | 2022 | |
| Axsome Therapeutics, INC. | $291.19 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $252.54 | 2021-2025 | Nuplazid |
| Amgen INC. | $249.44 | 2019-2025 | Uplizna, Aimovig |
| Allergan, INC. | $244.01 | 2019-2020 | |
| Harmony Biosciences LLC | $233.12 | 2023-2024 | Wakix |
| Janssen Pharmaceuticals, INC | $220.06 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $214.18 | 2023 | Uplizna |
| Ucb, INC. | $143.43 | 2023-2025 | Rystiggo |
| Biogen, INC. | $127.84 | 2022-2025 | Vumerity |
| Medtronic, INC. | $127.17 | 2024 | Percept PC Brainsense |
| E.R. Squibb & Sons, L.L.C. | $124.38 | 2024 | Zeposia |
| Kyowa Kirin, INC. | $123.46 | 2022 | |
| Jazz Pharmaceuticals INC. | $119.82 | 2024-2025 | |
| Celgene Corporation | $97.46 | 2025 | Zeposia |
| Aucta Pharmaceuticals, INC. | $88.98 | 2024-2025 | Motpoly Xr |
| Mdd US Operations, LLC | $72.70 | 2024 | Apokyn |
| Lundbeck LLC | $67.73 | 2025 | Vyepti, Rexulti |
| Sumitomo Pharma America, INC. | $66.10 | 2023 | Aptiom |
| Argenx US, INC. | $55.20 | 2025 | Vyvgart Hytrulo |
| Lilly USA, LLC | $51.62 | 2023-2024 | Amyvid |
| Scilex Pharmaceuticals INC. | $43.73 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $28.61 | 2019 | |
| Abbott Laboratories | $25.76 | 2025 | Infinity |
| Amneal Pharmaceuticals LLC | $23.99 | 2024 | Rytary |
| Csl Behring | $23.74 | 2024 | Hizentra |
| Octapharma USA, INC. | $22.36 | 2024 | Panzyga |
| Upsher-Smith Laboratories LLC | $21.36 | 2019 | |
| Genzyme Corporation | $20.00 | 2019 | |
| Forte Bio-Pharma LLC | $19.12 | 2025 | Tanlor |
| Livanova USA, INC. | $18.50 | 2020 | |
| Biomarin Pharmaceutical INC. | $16.58 | 2024 | Brineura |
| Azurity Pharmaceuticals, INC. | $14.58 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veena Sengupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.